SCHEMBL20951925

SCHEMBL20951925

NC(=O)C(N)CCCNC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OTC P00480 1/20 0.46
DDAH1 O94760 3/20 0.43
DPP7 Q9UHL4 2/20 0.43
GSR P00390 1/20 0.38
GNAI3 P08754 1/20 0.38
GNAO1 P09471 1/20 0.38
GNAI1 P63096 1/20 0.38
NOS2 P35228 3/20 0.37
CYP2C19 P33261 2/20 0.37
CYP1A2 P05177 1/20 0.37
GLA P06280 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37
APEX1 P27695 1/20 0.37
RRM1 P23921 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20168406 0.94 DPP7 (0.46) OTCDDAH1DPP7GSRGNAI3
SCHEMBL20168409 0.94 DPP7 (0.46) OTCDDAH1DPP7GSRGNAI3
SCHEMBL23111902 0.87 ALOX15 (0.37) OTCDDAH1DPP7GSRNOS2
SCHEMBL23111901 0.87 ALOX15 (0.37) OTCDDAH1DPP7GSRNOS2
SCHEMBL3169670 0.85 DPP7 (0.44) OTCDDAH1DPP7GSRGNAI3
SCHEMBL607463 0.85 DPP7 (0.44) OTCDDAH1DPP7GSRGNAI3
SCHEMBL18866881 0.85 DPP7 (0.44) OTCDDAH1DPP7GSRGNAI3
SCHEMBL30256813 0.82 DPP7 (0.42) OTCDDAH1DPP7GNAI3GNAO1
SCHEMBL598710 0.82 DPP7 (0.42) OTCDDAH1DPP7GNAI3GNAO1
SCHEMBL304115 0.82 DPP7 (0.42) OTCDDAH1DPP7GNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3988561-B1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPHARMA LTD (KY) 2023-06-07 EP disclosed
EP-3988561-A1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPharma Ltd. (KY) 2022-04-27 EP disclosed
US-11312703-B2 Reactive oxygen species scavengers and use for treating diseases XWPharma Ltd. (KY) 2022-04-26 US disclosed
EP-3679051-B1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPHARMA LTD (KY) 2021-12-29 EP disclosed
US-11046729-B2 Dipeptide analogs as TGF-beta inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2021-06-29 US disclosed
US-20210061791-A1 REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES XWPharma Ltd. (KY) 2021-03-04 US disclosed
EP-3700545-A1 DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS Southern Research Institute (US) 2020-09-02 EP disclosed
US-20190127420-A1 DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS UAB RESEARCH FOUNDATION 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127420-A1 DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS TGFB1, TGFB2, SMAD3 OTC 2908/4885DDAH1 1440/4885DPP7 21/4885
US-20210061791-A1 REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES GSR, TXNRD2, GPX1 OTC 115/4885DDAH1 1162/4885DPP7 3005/4885
US-11312703-B2 Reactive oxygen species scavengers and use for treating diseases GSR, TXNRD2, GPX1 OTC 115/4885DDAH1 1162/4885DPP7 3005/4885
US-11046729-B2 Dipeptide analogs as TGF-beta inhibitors TGFB1, TGFB2, SMAD3 OTC 2908/4885DDAH1 1440/4885DPP7 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.